ReviewJournal of immunology research2026
The Research Progress of Tumor-Associated Macrophages in Prostate Cancer.
Review in Journal of immunology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Lactobacillus plantarum-derived indole-3-lactic acid inhibits prostate cancer progression through ASF1B/ENO1 axis and remodels the tumor microenvironment to enhance anti-PD-1 therapy.Molecular biomedicine · 2026Article
- The Research Progress of Tumor-Associated Macrophages in Prostate Cancer.Journal of immunology research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Prostate cancer (PCa) is a major global cancer burden in men, and its treatment is hindered by the immunosuppressive tumor microenvironment. In this context, PCa initially shows a favorable response to immunotherapy. However, as the disease progresses, the tumor gradually develops resistance to immunotherapy, with tumor-associated macrophages (TAMs) being key drivers. TAMs promote inflammation, angiogenesis, stromal remodeling, and immune evasion, leading to the development of castration-resistant PCa. The traditional M1/M2 dichotomy, such as proliferative-TAM (Prolif-TAM) and immunoregulatory-TAM (Reg-TAM), has been refined by single-cell RNA sequencing. In this article, we further discuss how signaling pathways regulate TAM polarization and investigate the multidimensional mechanisms by which TAMs drive PCa progression, the pathways that promote immunotherapy resistance, and the role of macrophage extracellular traps (METs) in PCa metastasis. Targeting TAMs for precision treatment of PCa is a promising therapeutic strategy. These strategies include blocking the adenosine pathway to inhibit SPP1
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.